🏥 Health

Ozempic, Wegovy and GLP-1 Weight Loss Drugs: The Real Truth Americans Need to Know

Walter Hennery·July 19, 2026·10 min read

GLP-1 receptor agonist drugs " — the class that includes Ozempic, Wegovy, Mounjaro, and Zepbound " — have become a cultural phenomenon. Celebrities use them. Your neighbor might be on one. But beneath the hype, millions of Americans deserve honest answers to real questions: How effective are they really? Who should and shouldn't take them? What happens when you stop? And how do you access them if you can't afford $1,000+ per month?

What These Drugs Actually Do

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after you eat. It signals to your brain that you're full, slows gastric emptying, and stimulates insulin release. GLP-1 receptor agonist drugs mimic and amplify this hormone's effects. The result for most people is a dramatic reduction in appetite " — described by many patients as "food noise" going quiet for the first time in their lives.

The clinical trial results are striking: semaglutide (Ozempic/Wegovy) produced an average weight loss of 15"17% of body weight in clinical trials. Tirzepatide (Mounjaro/Zepbound) has shown average losses of 20"22% in some trials. These numbers were previously only associated with bariatric surgery.

The Side Effects Most Articles Gloss Over

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. More serious concerns that deserve attention:

Muscle loss: A significant portion of weight lost on GLP-1 drugs is muscle mass, not just fat " — particularly in people who aren't resistance training during treatment. Muscle loss has long-term metabolic consequences. Strength training during treatment is medically advisable, not optional.
Rebound weight gain: Clinical trials show clearly that when patients stop taking these drugs, the majority regain most of the weight within one to two years. These medications appear to require indefinite use for sustained effects " — which has significant cost and health monitoring implications.
Gastroparesis risk: A small number of patients have developed severe delayed gastric emptying that persisted even after stopping the medication.
Thyroid concerns: Animal studies showed increased risk of thyroid tumors. People with a personal or family history of medullary thyroid carcinoma are advised not to take these drugs.

Who Should (and Shouldn't) Consider These Medications

Current FDA approvals suggest these medications are appropriate for adults with a BMI of 30+ (obesity) or BMI of 27+ plus at least one weight-related health condition (Type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea).

People who should exercise extra caution: those with a history of pancreatitis, kidney disease, eating disorders, or gallbladder disease. A thorough conversation with a physician who knows your complete medical history is essential before starting.

How to Access These Medications If You Can't Afford $1,000/Month

Manufacturer savings programs: Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) offer savings programs that can reduce costs to $25"$200/month for eligible commercially insured patients.
Compounded semaglutide: During periods of drug shortage, compounding pharmacies produced semaglutide at $150"$400/month. Verify current legal status and use only FDA-registered compounding pharmacies.
Telehealth prescribers: Services like Found, Ro, and Calibrate can prescribe and manage GLP-1 therapy remotely, often at lower total cost than a traditional specialist visit.

Important: These are serious medications with real risks and real benefits. The decision to start GLP-1 therapy should be made with a qualified healthcare provider who knows your full medical history " — not based on what you've seen on social media or what a neighbor is doing.